Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Impact of Humira Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice -HOPE

Trial Profile

Impact of Humira Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice -HOPE

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Dec 2018

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Intermediate uveitis; Panuveitis; Posterior uveitis
  • Focus Therapeutic Use
  • Acronyms HOPE
  • Sponsors AbbVie
  • Most Recent Events

    • 22 May 2018 Planned End Date changed from 2 May 2019 to 31 Dec 2019.
    • 22 May 2018 Planned primary completion date changed from 2 May 2019 to 31 Dec 2019.
    • 16 Nov 2017 Planned End Date changed from 20 Jun 2019 to 2 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top